Skip to content

Prospective Phase III Trial of Hypofractionated Postmastectomy Radiation Therapy

Prospective Phase III Trial of Hypofractionated Postmastectomy Radiation Therapy

Status
Recruiting
Phases
Phase 3
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015067
Enrollment
Unknown
Registered
2018-03-06
Start date
2017-01-01
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

hypofractionated radiotherapy group:hypofractionated radiotherapy
conventional radiotherapy:onventional radiotherapy

Sponsors

Department of Radiation Oncology, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) patients voluntarily participate in study and sign informed consent; (2) female aged 18 and 70 years old; (3) patients following mastectomy with IIA (not including T2N0) ~ IIIC stage breast cancer, pathology is invasive carcinoma; (4) adjuvant chemotherapy was completed as scheduled; (5) patients with axillary lymph node metastasis was confirmed by imaging or clinical examination, pathology is invasive carcinoma and followed neoadjuvant chemotherapy; (6) patients with KPS= 80 and expected survival period is more than 12 months; (7) no serious underlying disease in the heart and lungs.

Exclusion criteria

Exclusion criteria: (1) patients with her-2 positive expression and didnt receive target treatment, ER/PR positive expression with no postoperative adjuvant endocrine therapy; (2) patients who had not completed postoperative adjuvant chemotherapy as scheduled; (3) there is a history of radiotherapy in the proposed irradiation area; (4) the treatment area has active connective tissue disease; (5) patients with severe complications and history of mental illness.

Design outcomes

Primary

MeasureTime frame
local recurrence-free survival;regional recurrence-free survival;acute adverse reaction;late complication;

Secondary

MeasureTime frame
distant metastasis-free survival;overall survival;

Countries

China

Contacts

Public ContactMa Lin

Department of Radiation Oncology, Chinese PLA General Hospital

malinpharm@sina.com+86 13911197589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026